✦ LIBER ✦

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089)

✍ Scribed by Barlesi, F.; Scherpereel, A.; Rittmeyer, A.; Pazzola, A.; Ferrer Tur, N.; Kim, J.-H.; Ahn, M.-J.; Aerts, J. G. J. V.; Gorbunova, V.; Vikstrom, A.; Wong, E. K.; Perez-Moreno, P.; Mitchell, L.; Groen, H. J. M.

Book ID: 121425990
Publisher: American Society of Clinical Oncology
Year: 2013
Tongue: English
Weight: 188 KB
Volume: 31
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2012.42.3749

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II Trial of First-line Bevacizum

A Phase II Trial of First-line Bevacizumab in Combination With Pemetrexed and Carboplatin in Advanced Nonsquamous Non–Small-Cell Lung Cancer: Preliminary Results

✍ Z. Skaff; A. Hageboutros; K. Krieger; S. Coakley; R. Somer; J. Stevenson 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 43 KB

PointBreak: A Randomized Phase III Study

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer

✍ Patel, J. D.; Socinski, M. A.; Garon, E. B.; Reynolds, C. H.; Spigel, D. R.; Ols 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 243 KB

9112 POSTER AVAPERL1 (MO22089) – Interim

9112 POSTER AVAPERL1 (MO22089) – Interim Safety of Maintenance (mtc) Bevacizumab (bev) + Pemetrexed (pern) in Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx)

✍ Ahn, M.; Gervais, R.; Mezger, J.; Reck, M.; Orlov, S.; Burgers, J.A.; Bearz, A.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Induction Pemetrexed and Cisplatin Follo

Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life–Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (ERACLE)

✍ Domenico Galetta; Salvatore Pisconti; Saverio Cinieri; Giovanni Luigi Pappagallo 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 235 KB

Treatment Rationale and Study Design for

Treatment Rationale and Study Design for a Randomized Trial of Pemetrexed/Carboplatin Followed by Maintenance Pemetrexed Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced Non–Small-Cell Lung Cancer of Nonsquamous Histology

✍ Ralph G. Zinner; Scott B. Saxman; Guangbin Peng; Matthew J. Monberg; Waldo I. Or 📂 Article 📅 2010 🏛 CIG Media Group, LP. 🌐 English ⚖ 122 KB

AVAPERL (MO22089): Final Efficacy Outcom

AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev + Pemetrexed (pern) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx)

✍ F Barlesi; J. de Castro; V. Dvornichenko; J.H. Kim; A. Pazzola; A. Rittmeyer; A. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 48 KB